Novartis AG vs Spotify Technology — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while Spotify Technology trades at $501.08 (market cap $105.22B). The key difference: Novartis AG is far larger — about 2.8× Spotify Technology's market cap, and Novartis AG pays a 3.02% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| NVS | SPOT | |
|---|---|---|
Market Cap | $298.18B | $105.22B |
Sector | Health | Media |
52-Week High | $168.62 | $738.53 |
52-Week Low | $119.31 | $412.75 |
Enterprise Value | $339.50B | $94.91B |
Dividend Yield | 3.02% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Spotify (SPOT) trades at $488.14, up 2.75% with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with Q2 2026 revenue growth of 14% year-over-year and record gross margins of 33.4%, though earnings missed expectations due to increased marketing and AI costs. Premium subscribers surpassed 300 million for the first time, supporting the long-term growth narrative.
Wall Street maintains a bullish outlook with 61.5% buy ratings and a $598.20 consensus price target representing 22.5% upside potential. Key risks include execution on AI investments, competitive pressure in streaming, and margin sustainability. The stock presents growth opportunity if monetization initiatives succeed.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →